© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 18, 1499-1507,
September 15, 1993
© 1993 Oxford University Press
Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor
Gastrointestinal Oncology Service, Division of Medical Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and The Cornell University Medical College New York, N.Y.
Developmental Chemotherapy Service, Division of Medical Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and The Cornell University Medical College New York, N.Y.
Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, and The Cornell University Medical College New York, N.Y.
Correspondence to: Leonard Saltz, M.D., Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021
BACKGROUND: Topotecan has been shown In previous studies to be a specific inhibitor of topoisomerase I, a nuclear enzyme required for DNA replication and transcription.
PURPOSE: Our objectives in this phase I clinical trial were to determine the maximum tolerated dose, dose-limiting toxic effects, and recommended phase II dose of topotecan and to define the pharmacokinetlcs of topotecan in humans.
METHODS: Forty-three patients with advanced, incurable solid tumors were treated. Doses ranged from 0.5 to 2.0 mg/m2 daily, with treatment cycles repeated initially every 28 days. Following the identification of the standard maximum tolerated dose, further dose escalations were attempted by following topotecan cycles with recombinant granulocyte colonystimulating factor (rG-CSF).
RESULTS: The maximum tolerated dose without rG-CSF for patients without prior cytotoxic therapy was 1.75 mg/m2 daily. The maximum tolerated dose for previously treated patients was 1.50 mg/m2 daily. The dose-limiting toxic effect was myelosuppression, with granulocytopenia being most commonly observed. Use of rG-CSF did not permit topotecan dose intensification, since thrombocytopenia and fatigue rapidly emerged as dose-limiting toxic effects. Plasma half-lives of topotecan (lactone form) were approximately 10 and 100 minutes for distribution and elimination phases, respectively.
CONCLUSIONS: The doses of topotecan recommended for use in phase II clinical trials in solid tumors are 1.5 and 1.25 mg/m2 daily in previously untreated and previously treated patients, respectively. Based on observed rates of recovery from myelosuppression, treatment should be possible on a 21-day cycle. Dose intensification was not possible with the use of rG-CSF; however, rG-CSF may be a useful addition to the regimens of those few patients who experience either prolonged granulocytopenia or neutropenic sepsis or those who are not able to receive their second treatment cycle by day 21. [J Natl Cancer Inst 85:1499–1507, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S.-i. Matsumoto, K. Yoshida, N. Ishiguro, T. Maeda, and I. Tamai Involvement of Rat and Human Organic Anion Transporter 3 in the Renal Tubular Secretion of Topotecan [(S)-9-Dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride] J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1246 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Masubuchi, R. D. May, and R. Atsumi A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the In vitro Colony-Forming Unit Granulocyte/Macrophage Assay Clin. Cancer Res., October 1, 2004; 10(19): 6722 - 6731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Armstrong Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity Oncologist, February 1, 2004; 9(1): 33 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Guarino, C. J. Schneider, S. S. Grubbs, D. D. Biggs, A. L. Himelstein, K. Hogaboom, and S. Tilak A Dose-Escalation Study of Weekly Topotecan, Cisplatin, and Gemcitabine Front-Line Therapy in Patients with Inoperable Non-Small Cell Lung Cancer Oncologist, December 1, 2002; 7(6): 509 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Furman, C. F. Stewart, M. Kirstein, J. L. Kepner, M. L. Bernstein, F. Kung, T. J. Vietti, C. P. Steuber, D. L. Becton, S. Baruchel, et al. Protracted Intermittent Schedule of Topotecan in Children With Refractory Acute Leukemia: A Pediatric Oncology Group Study J. Clin. Oncol., March 15, 2002; 20(6): 1617 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Seiden, S.-W. Ng, J. G. Supko, D. P. Ryan, J. W. Clark, T. Lynch, K.-C. Huang, D. Kwiatkowski, A. Skarin, and J. P. Eder Jr. A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors Clin. Cancer Res., March 1, 2002; 8(3): 691 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Schilder, J. M. Gallo, M. M. Millenson, M. A. Bookman, L. M. Weiner, A. Rogatko, B. Rogers, K. Padavic-Shallers, M. Boente, N. Rosenblum, et al. Phase I Trial of Multiple Cycles of High-Dose Carboplatin, Paclitaxel, and Topotecan With Peripheral-Blood Stem-Cell Support as Front-Line Therapy J. Clin. Oncol., February 15, 2001; 19(4): 1183 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rowinsky, T. R. Johnson, C. E. Geyer Jr, L. A. Hammond, S. G. Eckhardt, R. Drengler, L. Smetzer, J. Coyle, J. Rizzo, G. Schwartz, et al. DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies J. Clin. Oncol., September 17, 2000; 18(17): 3151 - 3163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M.M. Herben, R. van Gijn, J. H.M. Schellens, M. Schot, J. Lieverst, M. J.X. Hillebrand, N. E. Schoemaker, M. G. Porro, J. H. Beijnen, and W. W. ten Bokkel Huinink Phase I and Pharmacokinetic Study of a Daily Times 5 Short Intravenous Infusion Schedule of 9-Aminocamptothecin in a Colloidal Dispersion Formulation in Patients With Advanced Solid Tumors J. Clin. Oncol., June 1, 1999; 17(6): 1906 - 1906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M.M. Herben, V. R. Nannan Panday, D. J. Richel, J. H.M. Schellens, N. van der Vange, H. Rosing, F. D. Beusenberg, S. Hearn, E. Doyle, J. H. Beijnen, et al. Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian Cancer J. Clin. Oncol., March 1, 1999; 17(3): 747 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. H. Gerrits, J. H. M. Schellens, H. Burris, J. R. Eckardt, A. S. T. Planting, M. E. L. van der Burg, G. I. Rodriguez, W. J. Loos, V. van Beurden, I. Hudson, et al. A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin) Clin. Cancer Res., January 1, 1999; 5(1): 69 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-F. Héron Topotecan: An Oncologist's View Oncologist, December 1, 1998; 3(6): 390 - 402. [Abstract] [Full Text]
|
|
|
|
|
|
D. Armstrong and S. O'Reilly Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity Oncologist, February 1, 1998; 3(1): 4 - 10. [Abstract] [Full Text]
|
|